Not every couple who comes to a fertility specialist needs IVF. Not every couple who struggles to conceive has a condition that requires the full complexity of assisted reproductive technology to overcome. For many couples — particularly those where the primary problem is that ovulation is not occurring reliably — a simpler first step is available that, when correctly applied to the right patient, can be remarkably effective.
That first step is ovulation induction.
Ovulation induction is the use of medication to stimulate the development and release of one or more eggs in women who are not ovulating — or not ovulating regularly enough — to give conception a consistent monthly chance. It is not IVF. It does not involve egg retrieval or laboratory fertilization. In its simplest form, it is a course of tablets taken for five days at the beginning of the menstrual cycle, followed by timed intercourse or IUI at the appropriate time.
Yet despite its simplicity, ovulation induction — when it is the right treatment, applied correctly, with appropriate monitoring and with realistic expectations about who will benefit from it — can be the only intervention needed to produce a pregnancy in women who would otherwise wait months or years for the right natural cycle to coincide with the right circumstances.
This article explains what ovulation induction is, how it works, who it is appropriate for, what the medications involved are, what monitoring is required, and what the success rates look like. It is the foundation for understanding when this simpler treatment is the right starting point — and when, despite the appeal of a gentler first step, IVF or another approach is the clinically appropriate recommendation from the outset.
What Is Ovulation and Why Does It Sometimes Need to Be Induced?
Before understanding ovulation induction, it helps to understand ovulation itself — and what goes wrong when it does not happen as it should.
Ovulation is the release of a mature egg from a follicle in the ovary. It occurs once per menstrual cycle — typically around day fourteen of a standard twenty-eight-day cycle, though the timing varies significantly between women — and is triggered by a surge of luteinizing hormone (LH) from the pituitary gland. The released egg enters the fallopian tube, where it may be fertilized by sperm if intercourse has occurred within the appropriate window.
Ovulation is the essential prerequisite for natural conception. Without ovulation, there is no egg to fertilize, and conception cannot occur regardless of how healthy the sperm are, how open the fallopian tubes are, or how receptive the uterine environment is.
Several conditions cause ovulation to be absent or irregular.
Polycystic ovary syndrome (PCOS) is the most common cause of anovulation — the absence of ovulation — in women of reproductive age. In PCOS, the hormonal imbalance — elevated androgens, disrupted FSH and LH dynamics, and in many cases insulin resistance — prevents the normal sequential development of a dominant follicle and its release at ovulation. Women with PCOS may have very infrequent periods — sometimes only a few per year — or may appear to have regular cycles that are actually anovulatory.
Hypothalamic amenorrhea occurs when the hypothalamus — the brain region that regulates reproductive hormones — suppresses gonadotropin-releasing hormone (GnRH) production, typically in response to excessive physical or psychological stress, very low body weight, or extreme exercise. Without GnRH stimulation, the pituitary does not release FSH and LH, and without FSH and LH, the ovaries do not develop follicles or ovulate. Women with this condition typically have absent periods.
Hyperprolactinemia — elevated prolactin levels — suppresses ovulation by disrupting the hormonal signals from the pituitary. Causes include a benign pituitary tumor (prolactinoma), certain medications, and thyroid dysfunction. Treatment of the underlying cause — typically with medication — often restores ovulation without further intervention.
Thyroid dysfunction — both hypothyroidism and hyperthyroidism — disrupts the hormonal environment necessary for normal follicle development and ovulation. Correction of thyroid function frequently restores ovulation in women with thyroid-related menstrual irregularity.
Diminished ovarian reserve — reduced egg supply — can result in infrequent or absent ovulation as the remaining follicular pool becomes insufficient to support regular follicle development.
In all of these conditions, the common clinical problem is the same: eggs exist in the ovaries but are not being released consistently enough — or at all — to give conception a reliable monthly chance. Ovulation induction addresses this problem by providing the hormonal stimulus that the body is not producing adequately on its own.
The Medications Used for Ovulation Induction
Three main categories of medication are used for ovulation induction, each with its own mechanism, indications, and profile of advantages and limitations.
Letrozole — The Current First-Line Choice for PCOS
Letrozole is an aromatase inhibitor — a medication that blocks the enzyme aromatase, which converts androgens into estrogens in the body. By reducing estrogen levels temporarily, letrozole removes the negative feedback that estrogen exerts on the hypothalamus and pituitary, causing FSH release to increase and the ovaries to respond by developing a dominant follicle.
Letrozole is taken orally for five days at the beginning of the menstrual cycle — typically days two through six or three through seven. It is generally well tolerated. Side effects during the treatment days may include mild hot flushes, headache, and occasionally mood changes, but these are typically mild and resolve after the tablets are finished.
Letrozole has largely replaced clomiphene citrate as the first-line medication for ovulation induction in PCOS because it produces a lower multiple pregnancy rate and because it does not have the antiestrogenic effect on the endometrium that clomiphene carries. Multiple large randomized trials — including the landmark PPCOS II trial — have confirmed letrozole's superiority to clomiphene for ovulation induction in PCOS in terms of ovulation rates, pregnancy rates, and live birth rates.
Clomiphene Citrate — The Historical Standard
Clomiphene citrate has been used for ovulation induction for more than fifty years and was, until recently, the most widely prescribed fertility medication globally. It works by blocking estrogen receptors in the hypothalamus — fooling the brain into perceiving low estrogen and thereby stimulating increased FSH release and follicle development.
Like letrozole, clomiphene is taken orally for five days at the start of the menstrual cycle. It is effective at inducing ovulation in a significant proportion of anovulatory women — ovulation rates of 70 to 80 percent per cycle are reported in PCOS patients — but its live birth rates are lower than would be expected from these ovulation rates, partly because of its antiestrogenic effect on the endometrium (reducing lining thickness and receptivity) and partly because of its antiestrogenic effect on cervical mucus.
Clomiphene resistance — the failure to ovulate despite standard and escalating doses — occurs in approximately 20 to 25 percent of PCOS patients. Women who are obese, who have high baseline LH levels, or who have severe insulin resistance are more likely to be clomiphene-resistant.
In contemporary fertility practice, letrozole is the preferred first-line agent for ovulation induction in PCOS. Clomiphene retains a role in specific situations — including non-PCOS ovulatory dysfunction and in combination regimens — but has largely been superseded for the primary PCOS indication.
Gonadotropin Injections — for Resistant or Complex Cases
When oral medications — letrozole or clomiphene — fail to induce ovulation, or when ovulation occurs but pregnancy does not result after several cycles, injectable gonadotropins are the next step. Gonadotropins — FSH, LH, or combinations of both — are administered as subcutaneous injections, typically daily or every other day, from the early part of the menstrual cycle.
Gonadotropins directly stimulate follicle development by replacing the FSH signal that the pituitary is not providing in adequate amounts. They are more potent than oral agents and can stimulate follicle development in women who do not respond to clomiphene or letrozole. However, they carry a higher risk of multiple follicle development — and therefore multiple pregnancy — than oral agents, because the ovarian response to gonadotropins is less predictable and requires careful monitoring to avoid excessive stimulation.
Gonadotropins used for ovulation induction — as opposed to controlled ovarian hyperstimulation for IVF — are given at lower doses and with the intention of producing one or two dominant follicles rather than the five to fifteen of a full IVF stimulation. Close ultrasound monitoring is essential to ensure that the stimulation remains within the intended range and that cycles with excessive follicle development — where the multiple pregnancy risk is unacceptably high — are cancelled.
Monitoring During Ovulation Induction: Why It Matters
Ovulation induction is not a medication to be taken and forgotten. It requires monitoring — ultrasound assessment of follicle development during the stimulation phase — to confirm that ovulation is occurring as intended and to time the key clinical action (intercourse or IUI) to the appropriate window.
Monitoring serves several functions. It confirms that the medication is producing the expected follicle development — a single dominant follicle reaching maturity. It identifies cycles in which the response is inadequate — no follicle developing — allowing dose adjustment in the next cycle. It identifies cycles in which the response is excessive — three or more large follicles developing — in which case the cycle may be cancelled to avoid the risk of multiple pregnancy. And it identifies the optimal time for intercourse or IUI, maximizing the chance that sperm are present when ovulation occurs.
At Metro IVF, monitoring during ovulation induction involves at least one and typically two ultrasound scans per cycle — a mid-cycle scan to assess follicle development and, where indicated, a pre-trigger scan to confirm follicle maturity before the trigger injection.
The trigger injection — typically an hCG injection — is given when the lead follicle reaches 18 to 20 millimetres in diameter, completing the final maturation of the egg and triggering ovulation at a predictable time approximately 36 to 40 hours later. Timed intercourse or IUI is scheduled for this window.
Who Is a Good Candidate for Ovulation Induction?
Ovulation induction is the appropriate first step in a specific and well-defined clinical situation: the woman is anovulatory or oligo-ovulatory, and the other prerequisites for natural or IUI-assisted conception are in place.
Those prerequisites are critical. Before ovulation induction is recommended, the clinical assessment must confirm that the fallopian tubes are open and functional — because ovulation induction combined with timed intercourse or IUI depends on the tubes carrying the egg to meet the sperm, and blocked tubes render ovulation induction entirely ineffective regardless of how reliably it produces ovulation. The male partner's sperm must be adequate — not necessarily perfect, but of sufficient count and quality to achieve fertilization naturally or with the help of IUI preparation. And the woman's ovarian reserve must be sufficient to support follicle development in response to the chosen medication.
When these conditions are met — open tubes, adequate sperm, adequate reserve, and anovulation or oligovulation as the primary diagnosis — ovulation induction is a clinically rational and frequently effective first step.
When they are not met — blocked tubes, severely compromised sperm quality, severely diminished reserve, or a diagnosis that is not primarily ovulatory — ovulation induction is not the appropriate starting treatment. Beginning ovulation induction in a patient with blocked tubes, for example, is not a lower-intensity version of the right treatment. It is the wrong treatment applied to the wrong diagnosis.
Success Rates of Ovulation Induction
The success rate of ovulation induction depends on the patient's diagnosis, age, ovarian reserve, and the specific medication and protocol used.
In well-selected PCOS patients treated with letrozole — younger women with adequate reserve, open tubes, and adequate sperm — the live birth rate per ovulation induction cycle is approximately 15 to 25 percent. Across three to four cycles, the cumulative live birth rate approaches 50 percent, which is comparable to the cumulative success of IVF in some patient groups. In these patients, ovulation induction is a cost-effective, minimally invasive, and clinically appropriate first step before escalating to IVF.
In older patients, in patients with diminished reserve, or in patients where the response to oral agents has been poor, success rates are lower and the clinical case for earlier escalation to IVF is stronger.
The decision about how many ovulation induction cycles to attempt before escalating to IVF is an individualized one — based on age, response to medication, and the couple's specific circumstances. The general guidance — supported by the evidence — is that three to four well-monitored ovulation induction cycles in an appropriate candidate is a reasonable first-line approach. Beyond this, if pregnancy has not occurred, the probability of success with further ovulation induction cycles does not increase meaningfully, and escalation to IVF becomes the recommended next step.
The Relationship Between Ovulation Induction and IUI
Ovulation induction is frequently combined with IUI — intrauterine insemination — rather than with timed intercourse alone. The combination of an ovulation induction medication, ultrasound monitoring to confirm follicle development and trigger timing, and IUI to deliver prepared sperm directly into the uterine cavity is a well-established and effective clinical approach.
The rationale for adding IUI to ovulation induction rather than relying on timed intercourse is straightforward. IUI bypasses the cervix — removing the cervical mucus as a potential barrier to sperm transport — and delivers a concentrated sample of prepared sperm directly into the uterine cavity at the time of ovulation. For couples with mild male factor infertility, or for couples where cervical factor may be contributing to failure of timed intercourse, this combination can improve success rates meaningfully compared to ovulation induction with timed intercourse alone.
Whether to combine ovulation induction with IUI or to attempt timed intercourse first is an individualized decision based on the male partner's sperm parameters, the duration of infertility, and the specific clinical presentation. At Metro IVF, this decision is made after a thorough assessment of both partners — ensuring that the combination of ovulation induction and IUI is recommended when it adds genuine clinical value, not as a default approach applied to every patient.
When Ovulation Induction Is Not the Right Starting Point
As important as knowing when ovulation induction is appropriate is knowing when it is not — because recommending ovulation induction to patients for whom it cannot work wastes valuable time and delays access to the treatment that can actually succeed.
Ovulation induction is not appropriate as a starting treatment when the fallopian tubes are blocked — confirmed or suspected. It is not appropriate when the male partner's sperm parameters are severely compromised, making natural fertilization unreliable even with improved ovulation timing. It is not appropriate when the woman's ovarian reserve is so diminished that the medication cannot stimulate adequate follicle development. And it is not appropriate as a first step in women over 38 with unexplained infertility, where the time cost of multiple ovulation induction cycles before escalating to IVF may meaningfully compromise the cumulative probability of success.
These are the clinical boundaries within which ovulation induction operates — and respecting those boundaries is as important as applying the treatment correctly within them.
Your Next Step
If your periods are irregular, if you have been told you are not ovulating, or if you have PCOS and are trying to understand whether ovulation induction might be the right starting point for you — a consultation with Dr. Ashish Soni at Metro IVF in Ambikapur will give you the most complete and individualized assessment of your situation available.
The right first step is the one that is matched to your specific clinical picture. Finding out which step that is starts with one conversation.
Metro IVF Test Tube Baby Center Ambikapur, Chhattisgarh metrofertility.in Led by Dr. Ashish Soni — North India's First Fertility Super Specialist
The right treatment starts with the right diagnosis. Book your consultation with Dr. Ashish Soni at Metro IVF today — and find out where your fertility journey should begin.